News headlines about Catalyst Biosciences (NASDAQ:CBIO) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.9514652609368 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern’s rankings:

Several research analysts have weighed in on CBIO shares. Chardan Capital started coverage on shares of Catalyst Biosciences in a research note on Monday, June 12th. They set a “buy” rating and a $10.00 target price for the company. Ladenburg Thalmann Financial Services started coverage on shares of Catalyst Biosciences in a research note on Tuesday, June 6th. They set a “buy” rating and a $11.00 target price for the company. Finally, Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, June 5th.

Shares of Catalyst Biosciences (NASDAQ CBIO) traded up 5.59% on Friday, reaching $3.40. 20,516 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $3.92 and its 200-day moving average price is $5.15. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $21.30. The stock’s market capitalization is $14.65 million.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.46) by $1.07. Catalyst Biosciences had a negative return on equity of 92.61% and a negative net margin of 3,127.92%. The firm had revenue of $0.11 million for the quarter. Equities analysts predict that Catalyst Biosciences will post ($7.08) EPS for the current year.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Catalyst Biosciences (CBIO) Share Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Stock Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related stocks with our FREE daily email newsletter.